Organizational changes and layoffs that began in 2025 make me worry that the agency will struggle to fulfill its crucial mission ...
The US Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) have proposed a parallel review program to expedite certain Class II and Class III breakthrough ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results